363 related articles for article (PubMed ID: 24039977)
1. Metabolic glucose status and pituitary pathology portend therapeutic outcomes in acromegaly.
Cheng S; Al-Agha R; Araujo PB; Serri O; L Asa S; Ezzat S
PLoS One; 2013; 8(9):e73543. PubMed ID: 24039977
[TBL] [Abstract][Full Text] [Related]
2. Absence of immunostaining for growth hormone in a subset of patients with acromegaly.
Schroeder JL; Spiotta AM; Fleseriu M; Prayson RA; Hamrahian AH; Weil RJ
Pituitary; 2014 Apr; 17(2):103-8. PubMed ID: 23475513
[TBL] [Abstract][Full Text] [Related]
3. Pathology of acromegaly.
Horvath E; Kovacs K
Neuroendocrinology; 2006; 83(3-4):161-5. PubMed ID: 17047379
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine tumors secreting growth hormone-releasing hormone: Pathophysiological and clinical aspects.
Gola M; Doga M; Bonadonna S; Mazziotti G; Vescovi PP; Giustina A
Pituitary; 2006; 9(3):221-9. PubMed ID: 17036195
[TBL] [Abstract][Full Text] [Related]
6. Acromegaly.
Scacchi M; Cavagnini F
Pituitary; 2006; 9(4):297-303. PubMed ID: 17077948
[TBL] [Abstract][Full Text] [Related]
7. Acromegaly with normal growth hormone levels: response to Sandostatin-LAR treatment.
Shimon I; Nass D; Hadani M
Pituitary; 2000 May; 2(4):289-94. PubMed ID: 11081151
[TBL] [Abstract][Full Text] [Related]
8. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
[TBL] [Abstract][Full Text] [Related]
9. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
10. 'Silent' somatotropinoma.
Pawlikowski M; Kuta J; Fuss-Chmielewska J; Winczyk K
Endokrynol Pol; 2012; 63(2):88-91. PubMed ID: 22538745
[TBL] [Abstract][Full Text] [Related]
11. [Acromegaly--do we already know everything about treatment of the somatotroph pituitary adenomas?].
Zieliński G; Podgórski JK
Przegl Lek; 2002; 59(7):540-7. PubMed ID: 12516247
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SNARE proteins in human pituitary adenomas: targeted secretion inhibitors as a new strategy for the treatment of acromegaly?
Garcia EA; Trivellin G; Aflorei ED; Powell M; Grieve J; Alusi G; Pobereskin L; Shariati B; Cudlip S; Roncaroli F; Mendoza N; Grossman AB; Harper EA; Korbonits M
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1918-26. PubMed ID: 24152687
[TBL] [Abstract][Full Text] [Related]
13. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors of Acromegalic Patients with Growth Hormone-Secreting Pituitary Adenoma After Transsphenoidal Surgery.
Taweesomboonyat C; Oearsakul T
World Neurosurg; 2021 Feb; 146():e1360-e1366. PubMed ID: 33309643
[TBL] [Abstract][Full Text] [Related]
15. Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.
Lv L; Jiang Y; Yin S; Hu Y; Chen C; Ma W; Jiang S; Zhou P
Endocrine; 2019 Nov; 66(2):310-318. PubMed ID: 31368083
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of the growth hormone and type 1 insulin-like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor.
Kola B; Korbonits M; Diaz-Cano S; Kaltsas G; Morris DG; Jordan S; Metherell L; Powell M; Czirják S; Arnaldi G; Bustin S; Boscaro M; Mantero F; Grossman AB
Clin Endocrinol (Oxf); 2003 Sep; 59(3):328-38. PubMed ID: 12919156
[TBL] [Abstract][Full Text] [Related]
17. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
[TBL] [Abstract][Full Text] [Related]
18. In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide.
Ezzat S; Kontogeorgos G; Redelmeier DA; Horvath E; Harris AG; Kovacs K
Eur J Endocrinol; 1995 Dec; 133(6):686-90. PubMed ID: 8548053
[TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study.
Mo C; Chen H; Xu J; Guo Y; Wang Y; Li Z; Tong T; Gui S; Zhong L
Endocr Pract; 2024 May; 30(5):441-449. PubMed ID: 38307455
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form.
Obari A; Sano T; Ohyama K; Kudo E; Qian ZR; Yoneda A; Rayhan N; Mustafizur Rahman M; Yamada S
Endocr Pathol; 2008; 19(2):82-91. PubMed ID: 18629656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
